Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.
Ember, S.W., Lambert, Q.T., Berndt, N., Gunawan, S., Ayaz, M., Tauro, M., Zhu, J.Y., Cranfill, P.J., Greninger, P., Lynch, C.C., Benes, C.H., Lawrence, H.R., Reuther, G.W., Lawrence, N.J., Schonbrunn, E.(2017) Mol Cancer Ther 16: 1054-1067
- PubMed: 28336808 
- DOI: 10.1158/1535-7163.MCT-16-0568-T
- Primary Citation of Related Structures:  
5F5Z, 5F60, 5F61, 5F62, 5F63 - PubMed Abstract: 
Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers. Using the chemical scaffold of the JAK2 inhibitor TG101348, we developed and characterized single agents which potently and simultaneously inhibit BRD4 and a specific set of oncogenic tyrosine kinases including JAK2, FLT3, RET, and ROS1 ...